VALN Valneva Corp Future Profit

Valneva SE develops niche vaccines for travel medicine and defense needs, ensuring stable sales. The projected growth in net profit reflects market expectations, where the 0.06 parameter determines the metric's magnitude. High margins in narrow segments provide the company with significant pricing power. Simultaneously, Valneva SE is mitigating risks through R&D diversification and strategic alliances with global pharma behemoths.

VALN - Valneva Vaccines Expected Profit over the range 07/04/2022 - 11/14/2026

Valneva SE - analytical breakdowns and key metrics (VALN)

- share price and consensus valuation forecast:

Stock Price valneva.com|VALN - Analyst Consensus Forecast

- market capitalization data:

Market Valuation Valneva Pharma|VALN - Value Adjusted for Debt and Cash

- book capitalization information:

Accounting Value per Share Valneva|VALN - Company Book Value|Market Capitalization to Book Value Ratio valneva.com|VALN - Company Total Asset Base

- company total debt and liquidity indicators:

- earnings and market ratios statistics:

- company sales and revenue statistics:

VALN - Company Sales Revenue|Company Projected Revenue Valneva Corp|VALN - Price-to-Revenue Coefficient|Forward P/S Multiple Valneva

Basic company analysis:VALN, Valneva Corp

To assess stock reliability, it is necessary to differentiate market noise from fundamental stability by using the expected net income calculation as a measure of the business's real potential. Due to the pricing power of Valneva SE (VALN) in the mandatory vaccination segment, the profit change forecast on GURU.Markets reflects the monetization of a unique drug portfolio, where a stable curve confirms the issuer's high investment attractiveness.

Competitor analysis